Auspex Pharmaceuticals Company Profile (NASDAQ:ASPX)

About Auspex Pharmaceuticals (NASDAQ:ASPX)

Auspex Pharmaceuticals logoAuspex Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people with movement disorders and other rare diseases, including orphan diseases. Its pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea (abnormal involuntary movements) associated with Huntington's disease, an orphan disease, tardive dyskinesia and Tourette syndrome in the pediatric population, which is an orphan disease, as well as other orphan indications. Its lead product candidate is SD-809, which is a small molecule inhibitor of vesicular monoamine transporter 2 (VMAT2). Its other programs include SD-560, SD-1077 and SD-254.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ASPX
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $94.00
  • 200 Day Moving Avg: $59.00
  • 52 Week Range: $15.00 - $101.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -50.50
  • P/E Growth: 0
  • Return on Equity: -61.66%
  • Return on Assets: -50.55%
  • Average Volume: 634,233 shs.

Frequently Asked Questions for Auspex Pharmaceuticals (NASDAQ:ASPX)

What is Auspex Pharmaceuticals' stock symbol?

Auspex Pharmaceuticals trades on the NASDAQ under the ticker symbol "ASPX."

How were Auspex Pharmaceuticals' earnings last quarter?

Auspex Pharmaceuticals Inc (NASDAQ:ASPX) announced its quarterly earnings results on Monday, March, 16th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by $0.15. View Auspex Pharmaceuticals' Earnings History.

Who are some of Auspex Pharmaceuticals' key competitors?

How do I buy Auspex Pharmaceuticals stock?

Shares of Auspex Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Auspex Pharmaceuticals' stock price today?

One share of Auspex Pharmaceuticals stock can currently be purchased for approximately $101.00.

MarketBeat Community Rating for Auspex Pharmaceuticals (NASDAQ ASPX)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  64 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  112
MarketBeat's community ratings are surveys of what our community members think about Auspex Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Auspex Pharmaceuticals (NASDAQ:ASPX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Auspex Pharmaceuticals (NASDAQ:ASPX)
No equities research coverage for this company has been tracked by


Earnings History for Auspex Pharmaceuticals (NASDAQ:ASPX)
Earnings by Quarter for Auspex Pharmaceuticals (NASDAQ:ASPX)
Earnings History by Quarter for Auspex Pharmaceuticals (NASDAQ ASPX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/16/2015Q4 2014($0.59)($0.74)ViewN/AView Earnings Details
11/10/2014Q3 2014($0.45)($0.73)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.40)($0.45)ViewN/AView Earnings Details
5/13/2014Q114($0.47)($0.52)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Auspex Pharmaceuticals (NASDAQ:ASPX)
Current Year EPS Consensus Estimate: $-4 EPS
Next Year EPS Consensus Estimate: $-2 EPS


Dividend History for Auspex Pharmaceuticals (NASDAQ:ASPX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Auspex Pharmaceuticals (NASDAQ:ASPX)
Insider Trades by Quarter for Auspex Pharmaceuticals (NASDAQ:ASPX)
Insider Trades by Quarter for Auspex Pharmaceuticals (NASDAQ:ASPX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/16/2015David A StamlerInsiderSell3,000$80.00$240,000.00View SEC Filing  
2/13/2015Ventures Vii Lp CmeaMajor ShareholderSell122,667$63.08$7,737,834.36View SEC Filing  
2/11/2015Ventures Vii Lp CmeaMajor ShareholderSell84,154$61.06$5,138,443.24View SEC Filing  
2/6/2015Ventures Vii Lp CmeaMajor ShareholderSell93,179$59.39$5,533,900.81View SEC Filing  
1/28/2015Alex ZissonDirectorSell730,000$53.11$38,770,300.00View SEC Filing  
1/28/2015James E FlynnInsiderBuy1,500,000$56.50$84,750,000.00View SEC Filing  
1/28/2015Panorama Capital, L.P.Major ShareholderSell270,000$53.11$14,339,700.00View SEC Filing  
12/22/2014David A StamlerInsiderSell2,660$53.55$142,443.00View SEC Filing  
12/18/2014Ventures Vii Lp CmeaMajor ShareholderSell195,000$50.14$9,777,300.00View SEC Filing  
10/30/2014Ventures Vii Lp CmeaMajor ShareholderSell19,000$27.15$515,850.00View SEC Filing  
10/28/2014Ventures Vii Lp CmeaMajor ShareholderSell14,500$27.02$391,790.00View SEC Filing  
10/27/2014Ventures Vii Lp CmeaMajor ShareholderSell3,413$27.11$92,526.43View SEC Filing  
10/24/2014Ventures Vii Lp CmeaMajor ShareholderSell16,500$26.97$445,005.00View SEC Filing  
10/6/2014Ventures Vii Lp CmeaMajor ShareholderSell7,109$23.45$166,706.05View SEC Filing  
9/19/2014Gerald T ProehlDirectorBuy1,466$21.75$31,885.50View SEC Filing  
9/5/2014Ventures Vii Lp CmeaMajor ShareholderSell25,600$23.86$610,816.00View SEC Filing  
9/3/2014Ventures Vii Lp CmeaMajor ShareholderSell22,700$23.08$523,916.00View SEC Filing  
8/28/2014Ventures Vii Lp CmeaMajor ShareholderSell29,600$22.03$652,088.00View SEC Filing  
8/26/2014Ventures Vii Lp CmeaMajor ShareholderSell6,300$21.35$134,505.00View SEC Filing  
8/22/2014Ventures Vii Lp CmeaMajor ShareholderSell1,700$20.56$34,952.00View SEC Filing  
7/16/2014R Scott GreerDirectorBuy5,190$19.25$99,907.50View SEC Filing  
2/10/2014James E FlynnInsiderBuy700,000$12.00$8,400,000.00View SEC Filing  
2/10/2014Panorama Capital, L.P.Major ShareholderBuy333,334$12.00$4,000,008.00View SEC Filing  
2/10/2014Pratik ShahCEOBuy8,333$12.00$99,996.00View SEC Filing  
2/10/2014Sepehr SarsharDirectorBuy67,263$12.00$807,156.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Auspex Pharmaceuticals (NASDAQ:ASPX)
Latest Headlines for Auspex Pharmaceuticals (NASDAQ:ASPX)
DateHeadline logoSanofi Genzyme Reports Results From Phase 2 Open-Label Extension Study - July 10 at 4:07 PM logoAvexis Inc. (AVXS): RA Capital Management Ups Its Stake - April 13 at 8:52 PM logoChardan Analyst Suggests An AveXis-Ionis Pair Trade - February 6 at 3:43 PM logoHurry! These 5 Stocks Are About to Break Out Explosively - January 13 at 4:10 PM logoCitron Research On AveXis: This Will Be One Of 2017's Biotech Blowups - December 15 at 3:28 PM logoPharma, Biotech Shares Down After Trump Pledge To Cut Drug Prices - December 8 at 3:55 PM logoAll Eyes on These Two Biotech Firms Ahead of FDA Decisions (VCEL, SGYP) - December 8 at 3:55 PM logoShould You Sell AveXis (AVXS) Before Earnings? - November 9 at 12:31 PM logoCan The Uptrend Continue for AveXis (AVXS)? - November 4 at 2:00 PM logoHere's Why AveXis Shot Up 24.5% Today - November 2 at 3:58 PM logoIf you want to know which way the market is heading, follow the leaders - October 17 at 3:35 PM logoAveXis (AVXS) Shows Strength: Stock Adds 6.3% in Session - September 20 at 9:32 AM logoWhy AveXis (AVXS) Might Surprise This Earnings Season - August 9 at 12:26 PM logoRon Baron's Top New Stock Holdings - May 31 at 11:15 PM logoWhy Teva’s Specialty Medicines Performance Declined in 1Q15 - May 8 at 11:07 PM logoAUSPEX PHARMACEUTICALS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquis - May 5 at 4:50 PM logoTeva 1Q15 Earnings Preview: Stock Up 10.3% since Last Quarter - April 29 at 3:06 AM logoTeva Earnings Preview: Auspex Acquisition to Support Growth - April 28 at 9:06 PM logoMylan rejects Teva's $40.1 billion buyout offer - April 27 at 11:35 AM logoInvesting in IPOs: Why Investors Should Proceed with Caution - April 20 at 8:02 AM logoAUSPEX PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - April 17 at 9:02 AM logoThe Bull Case: Supply & Demand Edition - March 31 at 10:14 AM logoGLOBAL MARKETS-Stocks rally on merger activity; dollar gains - March 30 at 4:38 PM



Auspex Pharmaceuticals (ASPX) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by Staff